Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease

The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease. The post Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a…

Read More

Greg Whisman, Caremore

Greg Whisman is the Chief Medical Officer of Caremore, a venerable prepaid medical group caring for seniors. It’s been part of Anthem/Elevance for many years but this year spun off as part of a larger PE backed group called Millennium. We really got into the what and the how of primary care for seniors and,…

Read More

What We Know So Far About 2026 ACA Marketplace Enrollment, Premiums, and Deductibles

This analysis examines early indicators of how the expiration of enhanced premium tax credits has affected effectuated enrollment levels (i.e., enrollment among people who have paid their premiums), plan selections, and out-of-pocket costs in 2026, drawing on plan selection and effectuated enrollment data from the Centers for Medicare & Medicaid Services (CMS) and state-based Marketplace…

Read More